Research Article - (2014) Volume 2, Issue 3
Engraftment of Human Primary Acute Myeloid Leukemia Defined by Integrated Genetic Profiling in NOD/SCID/IL2rγnull Mice for Preclinical Ceramide-Based Therapeutic Evaluation
- Brian M Barth1,2*, Nichole R Keasey1,2, Xujung Wang1,2, Sriram S Shanmugavelandy3, Raajit Rampal4,5, Todd Hricik4,5, Myles C Cabot6, Mark Kester7, Hong- Gang Wang2,3,8, Leonard D Shultz9, Martin S Tallman4, Ross L Levine4,5, Thomas P Loughran Jr7 and David F Claxton1,2
- 1Department of Medicine, Penn State College of Medicine, Hershey, USA
- 2Penn State Hershey Cancer Institute, Penn State College of Medicine, Hershey, USA
- 3Department of Pharmacology, Penn State College of Medicine, Hershey, USA
- 4Leukemia Service, Department of Medicine, Memorial Sloan-Kettering Cancer Center, USA
- 5Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, USA
- 6Department of Biochemistry and Molecular Biology, East Carolina University, Greenville, USA
- 7University of Virginia Cancer Center, Charlottesville, USA
- 8Department of Pediatrics, Penn State College of Medicine, Hershey, USA
- 9The Jackson Laboratory, Bar Harbor, USA
*Corresponding Author:
Dr. Brian M Barth, Department of Medicine, Division of Hematology and Oncology, Penn State Hershey Cancer Institute, Penn State College of Medicine, 500 University Drive, PO Box 850, CH46 Hershey, PA 17033, USA, Tel: 717-531-0003 (289457)
Email:
